A New Era in TGCT Treatment: Novel Targeted Therapies and Their Effect on Shared Decision Making
William D. Tap, MD
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Iwona Misiuta, PhD, MHA
Clinical Content Manager
Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Upon completion, participants should be able to:
- Describe the mechanisms of action, efficacy, and safety of emerging therapies in clinical development for TGCT
- Select appropriate treatment strategies for patients with TGCT, including in the context of clinical trial enrollment, based on recent clinical evidence, expert perspectives, and patient preferences
This activity is intended for medical oncologists, surgeons, and rheumatologists.
Statement of Need
TGCT is a rare, local, aggressive, heterogeneous, benign tumor associated with joint destruction, inflammation, pain, and swelling, which can result in significant impairment to physical function and have a profound effect on patients’ quality of life. It has an estimated annual incidence of 11 to 50 cases per 1 million individuals. Until recently, the current standard of care for TGCT was surgical resection of the tumor; however, not every person is a candidate for surgery. Research has shown that TGCT cells overexpress colony-stimulating factor 1 (CSF1), which leads to the recruitment of CSF1 receptor (CSF1R)-positive tumor-associated macrophages and drives tumor growth and progression. This finding has led to the development of CSF1R inhibitors. Clinicians need to be aware of the clinical data on the efficacy and safety of these agents, as well as their potential use, so that they are prepared to incorporate them into clinical practice as they become available.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Medium/Method of Participation
This CME activity consists of a 0.75-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: November 26, 2019
Expiration Date: November 25, 2020
Estimated Time to Complete This Activity: 45 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
William D. Tap, MD
Royalty: Companion Diagnostics
Receipt of intellectual property right/patent holder: Companion Diagnostics
Consulting fees/advisory boards: Blueprint Medicines, Daiichi Sankyo, Co., Ltd., Deciphera, Eli Lilly and Company, EMD Serono, Inc., Nanno Carrier
Ownership interest (stocks/stock options – excluding mutual funds): Atropos Therapeutics, Certis Oncology Solutions
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email email@example.com.
Operating system - Med-IQ supports the following operating systems:
- Microsoft Windows supported by Microsoft
- Mac OS supported by Apple
Browsers - Med-IQ supports the current version of each browser listed below, plus two prior versions:
Microsoft Internet Explorer
- Microsoft Edge
Operating system - Med-IQ supports the current operating system, plus two prior releases:
- Android (eg, Samsung Galaxy)
- Apple (eg, iPhone/iPad)
Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
- Android (Chrome)
- Apple (Safari)
Applications & Software
PDF Viewer - Adobe Acrobat Reader or Adobe Reader
Adobe Flash Player - Med-IQ supports the current version, plus two prior versions
For technical assistance, please refer to our Support Manual.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
© 2019 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.